(Sharecast News) - American pharma and medical giant Johnson & Johnson has announced the $3.05bn acquisition of clinical-stage biotech company Halda Therapeutics in hopes that the company can revolutionise the treatment of cancer.
Halda's lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer with a novel approach to the selective...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE